文献速递肥胖与代谢综合征糖尿病

GLP-1类似物调节肥胖成人食欲、味觉偏好、肠道激素及区域体脂分布

GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

结果显示利拉鲁肽显著降低最大耐受量、预期进食量及对甜咸鲜脂肪食物的渴望,增加饱腹感,并减少全身、躯干及上下肢体脂而不减少瘦体重。

要点

  • 利拉鲁肽3 mg显著降低最大耐受量及预期进食量,增加饱腹感。
  • 利拉鲁肽减少对甜、咸、鲜、脂肪食物的渴望,调节味觉偏好。
  • 利拉鲁肽减少全身、躯干及上下肢体脂,不减少瘦体重。

核心结论

  • 利拉鲁肽3 mg皮下注射可调节肥胖成人的食欲、味觉偏好、肠道激素及区域体脂分布,且不减少瘦体重。

主要发现

  • 与安慰剂组相比,利拉鲁肽组最大耐受量、预期进食量及对甜、咸、鲜、脂肪食物的渴望显著降低,感知饱腹感增加。
  • 利拉鲁肽组餐后血浆GLP-1水平较基线下降,PYY水平较基线升高。
  • 利拉鲁肽组全身、躯干及上下肢体脂显著减少,瘦体重未减少。

临床怎么用

  • 利拉鲁肽3 mg可用于肥胖成人减重管理,通过调节食欲和味觉偏好减少体脂并保留瘦体重。

局限性

  • 原文未报告具体效应量、置信区间及P值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Obesity is associated with alterations in appetite, gastrointestinal hormone levels and excessive fat mass. We previously published a double-blind, placebo-controlled, randomized, 16-week trial on effects of once-daily glucagon-like peptide-1 (GLP-1) analog, liraglutide on weight, satiation, and gastric functions in obese volunteers. The aim of this substudy is to compare to placebo the effects of liraglutide on appetite, taste preference, regional body fat stores, and anthropometric measurements. METHODS: Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily). At baseline and 16 weeks, the following were measured: appetite and taste preferences rated every 30 min for 5 h after ingesting 300 mL Ensure®; maximal tolerated volume (MTV) with a nutrient drink test; fasting and postprandial bioactive GLP-1 (7-36) and peptide YY (PYY) levels; total and regional body fat with dual-energy X-ray absorptiometry, and waist and hip circumference. RESULTS: Thirty-five participants (17 liraglutide; 18 placebo) completed the trial. Compared to placebo group, liraglutide group had significant reductions in MTV; prospective food consumption score; desire to eat something sweet, salty, savory or fatty; and an increase in perceived fullness. Postprandial plasma levels of GLP-1 decreased and PYY levels increased with liraglutide relative to baseline. Significant reductions in total body, trunk, and upper and lower body fat without reduction in lean body mass were observed. CONCLUSION: Liraglutide 3 mg SQ modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity without reduction in lean body mass.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kadouh H, Chedid V, Halawi H, et al. GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity. J Clin Endocrinol Metab. 2020. PMID: 31665455. doi:10.1210/clinem/dgz140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。